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Abstract 
Despite the combined antiretroviral therapy has improved the length and quality of life of HIV infected patients, the 
survival of these patients is always decreased compared with the general population. This is the consequence of non-
infectious illnesses including cardio vascular diseases. In fact large studies have indicated an increased risk of coronary 
atherosclerotic disease, myocardial infarction even in HIV patients on cART. In HIV infected patients several factors may 
contribute to the pathogenesis of cardiovascular problems: life-style, metabolic parameters, genetic predisposition, 
viral factors, immune activation, chronic inflammation and side effects of antiretroviral therapy. The same factors may 
also contribute to complicate the clinical management of these patients. Therefore, treatment of these non-infectious 
illnesses in HIV infected population is an emerging challenge for physicians. The purpose of this review is to focus on 
the new insights in non AIDS-related cardiovascular diseases in patients with suppressed HIV viremia.
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A change of perspectives in the management 
of HIV infection: from an infectious disease to an 
internal medicine illness
The introduction of potent combined antiretroviral ther-
apy (cART) has dramatically increased the survival of 
HIV infected patients and has changed their causes of 
morbidity and mortality from AIDS-related opportunis-
tic infections to serious non AIDS events (SNAEs) [1].
Currently achieving undetectable viral load has become 
the minimum objective achievable with antiretroviral 
therapy; otherwise the safety of the therapy, the reduction 
of residual viremia, the eradication of the virus from the 
reservoirs and the reduction of the process of immune 
activation and chronic inflammation are still challenges 
for scientific research.
In particular to date is not well cleared the mecha-
nisms for the establishment and maintenance of 
chronic immune activation. All available data suppose 
the presence of multiple and complex mechanisms 
acting synergistically and may contribute to the patho-
genesis of SNAEs: viral factors, microbial transloca-
tion (MT), immune activation, systemic inflammation 
and side effects of therapy. Residual viremia, defined 
as the continuous persistence of the virus also at low 
levels despite effective cART, could be responsible of 
the chronic generalized inflammation and of the acti-
vation of the coagulation system. In addition the dam-
age of mucosal barrier in the gastrointestinal tract (GI) 
increases MT into the circulating blood and increase 
the risk of systemic complication such as immune 
activation.
The deleterious effect of the status of immune activa-
tion on the host immune system is still unclear. Undoubt-
edly an important consequence of the general status of 
inflammation is the ability of HIV to infect and kill acti-
vated CD4 T-helper cells with the impaired homeostasis 
of CD4 T cells and memory B cells by the fibrosis of lym-
phoid tissue; all that may contribute to the consequent 
inability of the host to control a wide range of poten-
tial pathogens. In fact the persistent immune activation 
makes CD4 T cells more susceptible to infection and 
causes a vicious cycle increasing the production of solu-
ble inflammatory markers such as IFN-γ, inflammatory 
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cytokines (i.e. IL-6) and indoleamine 2,3-dioxygenase 
(IDO) [2–7].
The excellent results now routinely achieved by cART 
have made the occurrence of opportunistic infections 
increasingly less frequent; at this time however it is 
common to observe cases of patients with undetectable 
blood levels of HIV-RNA, significant recovery of immu-
nological status and SNAEs including cardiovascular 
diseases (Fig.  1). For this reasons it becomes always 
more intriguing to know the pathogenesis and clinical 
characteristics of SNAEs during HIV infection to cure 
them.
The cardiovascular disease: a challenge for the cure 
of HIV patients
Epidemiology of cardiovascular diseases in HIV positive 
patients
A large body of evidences in scientific literature supports 
the epidemiological observation of an increase of mor-
bidity and mortality related to clinical and sub-clinical 
cardiovascular diseases (CVD) in HIV patients in the era 
of cART. A significantly higher risk of acute myocardial 
infarction (AMI) was observed in HIV infected patients 
compared with uninfected in veterans aging cohort study 
virtual cohort (VACS-VC) that analyzed data collected 
Fig. 1 Hypothesis of premature and accelerated of cardiovascular system aging in cARV treated HIV-infected patients
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in 82,459 veterans followed for an average of 5.9  years; 
unexpectedly the highest risk was found in patients in 
cART and with HIV-RNA less than 500  copies/ml [8]. 
Also Silverberg et al. [9] reported an higher risk of AMI 
among HIV+  patients with a low recent or nadir CD4 
cells (<200) compared with HIV-subject in a cohort study 
population included 22,081 HIV positive and 230,069 
HIV negative subjects.
In contrast Klein et al. [10] reported a decline of CVD 
in HIV patients as observed by the analysis of the data 
of Kaiser Permanente Southern California and North-
ern California health plans including 24,768 HIV posi-
tive patients and 257,600 controls. By these data the 
adjusted relative risk of AMI in HIV+ patients declined 
from 1.8 in 1996–1999 to 1.0 in 2010–2011 possibly due 
to the better control of the traditional CVD risk factors, 
the lower incidence of severe immunodeficiency, and the 
use of more lipid-friendly cART in the patients enrolled 
in this study.
Although the data reported by Klein et  al. probably 
influenced by the specific characteristics of their cohort, 
epidemiological studies show a significant overall impact 
of HIV on CVD. Since the size of the problem (although 
decreased after the introduction of lipid free antiretrovi-
ral drugs) remains very important, the actual aim of HIV 
medical practitioners is to better understand the kind 
of cardiovascular (CV) prevention to be applied to HIV 
population.
Recent retrospective and prospective studies evaluating 
the epidemiology of CVD in HIV positive patients were 
reported in Table 1.
The premature aging of cardiovascular system driven 
by chronic inflammation and immune activation
Many factors may contribute to the increase of incidence 
of CVD in HIV infected patients: the traditional deter-
minants of disease (cigarette smoking, diabetes mellitus, 
dyslipidemia, obesity, systemic hypertension, sedentary 
lifestyle, stress and family history of coronary artery or 
vascular disease) appear to be more common than in 
HIV negative population [11–13]. Moreover alterations 
of regulation of glucose  homeostasis  and  lipid  metabo-
lism and metabolic syndrome are frequently related with 
cART and are higher in patients previous treated with 
older antiretroviral drugs [14].
Anyway the excess risk of CVD observed in course of 
HIV infection cannot be explained only by the factors 
mentioned above. Several studies have also observed that 
co-morbidities, like CVD, which are normally witnessed 
later on in life as a result of natural aging, were increas-
ingly prominent among the HIV-infected population 
[15, 16]. These observations led to the hypothesis that 
the cART treated HIV-infected patients experienced a 
premature and accelerated aging probably driven by side 
effects of antiretroviral drugs, chronic inflammation and 
persistent immune activation (Fig. 1).
Undoubtedly a pivotal role in the development of accel-
erated aging of cardiovascular system and in the patho-
genesis of CVD is attributed to the status of immune 
activation. In fact in HIV patients the levels of proin-
flammatory cytokines and biomarkers associated to 
endothelial dysfunction are always higher and they can 
accelerated the atherosclerosis process. For example 
monocyte activation caused by microbial translocation 
drives the releases of soluble CD14 and CD163: the first 
is associated to increased death and the second with the 
risk of coronary artery progression and atherosclerosis 
[17–20]. High levels of these inflammatory markers and 
of factors of hypercoagulation (i.e. D-dimers, fibrino-
gen) are linked to systemic clotting and chronic inflam-
matory damage of vascular endothelium [21]. Also HIV 
itself is considered responsible of persistent immune 
activation and endothelial dysfunction in fact it can pen-
etrate into endothelial cells by receptor of CD4-T cells 
or chemokine receptors pathway. Moreover some HIV 
viral proteins, such as Gp120 and tumor necrosis-alpha 
(TNF-α), induce important consequences on the vascular 
tone, on the adhesion and aggregation of the platelet by 
the decrease of nitric oxide (NO) levels in the endothe-
lial cell [22–24]. The residual viremia may be the source 
of harm linked directly to the presence of the virus in 
course of effective cART, but may also be linked to the 
maintenance of the process of chronic inflammation and 
persistent immune activation.
Also Cytomegalovirus (CMV) infection appears to have 
a role in the premature aging of CV system: in a large 
Italian cohort CMV/HIV co-infection was associated 
with the risk of non-AIDS events including CV events 
independently of other prognostic factors. The potential 
role of CMV infection in CV disorders could depend by 
the complex interplay between viral and immunological 
activation, culminating in cyclical growth, damage and 
repair of endothelial cells. In fact from a pathogenic point 
of view, CMV can promote abnormal growth of endothe-
lial cells and pathogenesis of atherosclerosis enhanced 
by proangiogenic factors including IL-6 and granulocyte 
macrophage colony stimulating factor [25, 26].
For this reason, the research’s interest is to understand 
the hidden inflammatory causes of CVD in HIV patients 
and the first objective is to control the levels of persistent 
immune activation. In fact, to date, immunological thera-
peutic strategies and virological interventions are inves-
tigated with the aim of controlling the levels of immune 
activation and then reduce the impact of CVD promoted 
by chronic inflammation. Table 2 shows the studies, reg-
istered on https://www.clinicaltrials.gov and classified as 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 6 of 17d’Ettorre et al. AIDS Res Ther  (2016) 13:21 
“open”, and provides highlights for the current and future 
research topics in this area.
Current trends and challenges in evaluation of CV risk 
in HIV positive patients
As previous described, an increase of morbidity and 
mortality related to clinical and sub-clinical CVD in HIV 
patients are reported. An important paradigm in the 
comprehension of this increased incidence is to under-
stand the role of traditional risk factors. Evaluating the 
HIV cohorts, numerous data suggest that the prevalence 
of “traditional” risk factors is higher in HIV subjects 
if compared with general population. Triant et  al. [27] 
observed greater incidence of hypertension (HIV: 21.2 
vs. non-HIV: 15.9  %; p  <  0.001), diabetes (HIV: 11.5 vs. 
non-HIV: 6.6 %; p < 0.0001), and dyslipidemia (HIV: 23.3 
vs. non-HIV: 17.6 %; p < 0.0001) in HIV positive patients 
than in the controls. In particular, the serum triglycer-
ide levels are higher in HIV population respect to con-
trols [28]. Moreover, triglycerides work in a synergic way 
with both infection and cART: in fact, triglycerides levels 
increase when signs and symptoms of AIDS appear but 
also their serum levels are raised by protease inhibitors 
therapy [29].
However the high prevalence of “traditional” risk fac-
tors do not seem to be sufficient to explain the increased 
cardiovascular risk observed in the HIV positive popu-
lation and the cardiovascular risk assessment based on 
conventional risk prediction models (i.e. Framingham 
system, PROCAM, SCORE) does not offer a good pre-
dictive value for the HIV-positive population [30]. In 
fact cardiovascular risk scores were built for general 
population, and were not validated in the HIV positive 
population. Probably the factors that most affect the 
failure in estimating the cardiovascular risk in HIV-pos-
itive patients are HIV infection itself and the premature 
aging of CV system driven by chronic inflammation and 
immune activation: in this sense the virus may be con-
sidered “the missing factor” essential for a correct evalua-
tion of the overall risk [31].
Given the inadequacy of the risk estimation algorithms 
available, recently new models of risk prediction, specific 
for HIV-positive patients, were designed: for example 
Friis-Moller et  al. [31] proposed the Data Collection on 
Adverse Effects of Anti-HIV Drugs (D:A:D) study equa-
tion in which age, sex, systolic blood pressure, serum 
cholesterol total and HDL-cholesterol level, diabetes, 
smoking status, family history of CVD, current use of 
abacavir, indinavir, or lopinavir; and the number of years 
on indinavir or lopinavir were the variables included. 
This cardiac risk model  was created based upon data 
from the large cohort of HIV-infected patients who were 
followed longitudinally for cardiac events and performed 
better than the Framingham risk score among patients 
in that cohort. Moreover increased C-reactive protein 
(CRP) levels, uncontrolled HIV viral load at time of CV 
event and slower immunologic response were found to 
be associated with increased CVD risk in D:A:D: cohort 
[32]. Anyway a recent study of Thompson-Paul et al. [33] 
evaluating the D:A:D score and comparing with tradi-
tional algorithm for CV risk evaluation in HIV negative 
patients, highlighted that also the use of this algorithm 
was associated with the underestimation of CV risk. The 
authors concluded underlying that to better estimate 
CV risk in HIV-infected persons, additional risk factors, 
such as immunologic or virologic status may need to be 
considered.
The failure of traditional methods of CV risk assess-
ment has made it necessary to evaluate new methods to 
better understand the risk of CVD in HIV population.
Among the inflammatory biomarkers of CV risk, 
several have been proposed for diagnostic use, includ-
ing IL-6, D-dimer, MMP-9, and high-sensitivity CRP 
(hsCRP).  In HIV seronegative patients, hsCRP has 
emerged as the most useful because it has been proven 
to add risk to the other factors described within the 
Framingham cohort. Anyway for the time being, the 
meaning of hsCRP cannot be relied upon in the same 
manner in patients with HIV infection, in fact the results 
of studies in this setting are conflicting [34, 35].
In the field of diagnostic imaging, carotid intima-media 
thickness (cIMT), brachial ankle pulse wave velocity and 
coronary artery calcium (CAC) score are innovative indi-
cators for assessment of subclinical atherosclerosis and 
could give information about the development of CVD in 
patient without history of atherosclerotic diseases. These 
cardiovascular disease risk surrogate markers, are cur-
rently relegated to a secondary role, anyway their results 
should be considered complementary, and not alterna-
tive, to the information provided by CVD risk scores. 
In fact CVD risk assessment algorithms were not devel-
oped to predict coronary or carotid atherosclerosis, but 
rather cardiovascular events depending on the algorithm. 
For example baseline levels and change in  levels of sub-
clinical atherosclerosis, assessed by cIMT, could provide 
additional informations to determine how intensively to 
intervene on lifestyle and whether medication in corre-
spondence with individual’s cardiovascular risk factors is 
indicated [36–40].
Therefore in the last years the search for an optimal 
algorithm for estimating cardiovascular risk has been 
partly replaced by the search for exams increasingly 
able to estimate directly the presence of subclinical ath-
erosclerotic lesions. The prevention is therefore increas-
ingly moving towards the ability to diagnose the presence 
of silent atherosclerotic lesions able to progress and to 
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determine a significant symptoms in asymptomatic sub-
jects. On the basis of the above considerations the diag-
nostic applications of molecular imaging techniques 
becomes always more important in the detection of 
atherosclerotic plaques. The imaging by 18-fluoredeoxy-
glucose positron emission tomography (PET) and single 
photon emission computed tomography (SPECT) are 
considered important to identify activated macrophages 
infiltrating the arterial wall. Moreover both PET and 
SPECT provide information about the risk of plaque 
rupture and furthermore evaluate the vulnerability of 
itself. Recently Knudsen et  al. conducted a prospective 
cross sectional study in which 56 HIV positive patients 
and 25 controls were scanned using 82Rb PET to obtain 
the stress flow (MFR). The results obtained were strati-
fied in: low <1.5, borderline >1.5–2 or normal >2 and the 
Author did not observe difference between HIV positive 
and negative controls [41]. The data about the use of PET 
and SPECT in HIV population are not enough to con-
clude the useful of that in the real life. On the other hand 
the utility of imaging techniques in the detection of sub-
clinical atherosclerotic plaques was reported in a cross-
sectional study using dual-source CT (MDCT) coronary 
angiography conducted in HIV-infected subjects with 
low CV risk: MDCT showed an unexpected, age-associ-
ated high rate of significant coronary stenosis requiring 
coronary angiography in 29.1  % of asymptomatic HIV 
positive subjects enrolled. On the basis of these find-
ings authors suggested that MDCT may be appropriate 
for CVD screening programs in HIV positive population 
[42].
Detection of subclinical atherosclerosis by noninva-
sive tests such as CAC score, cIMT, MDCT, and PET 
may improve risk prediction above that of established 
risk scoring models. Moreover interesting results are 
expected by promising innovative techniques, such as 
3D quantification of carotid plaque by ultrasound (as in 
the Bioimage study), which are still waiting to be properly 
tested in HIV-positive population.
However, despite the interesting results obtained, more 
studies are need to investigate if diagnostic imaging 
exams can be used to guide patient screening, manage-
ment and therapy in HIV setting.
Clinical impact of inflammation on cardiovascular 
system: from subclinical atherosclerosis to complications 
of coronary revascularization
As previously reported, HIV-infected patients receiving 
combination antiretroviral therapy may experience meta-
bolic complications (i.e. dyslipidemia, impaired glucose 
metabolism and abnormal body fat distribution), poten-
tially increasing their risk of cardiovascular diseases. In 
fact HIV infection is associated with a marked rise in the 
frequency of coronary heart disease and with accelerated 
coronary atherosclerosis and vasculopathy.
The progression from subclinical atherosclerosis to 
symptomatic disease is estimated to be higher and earlier 
in HIV patients than in general population. In fact HIV 
patients have a high burden of subclinical atherosclerosis 
including an increased amount of non-calcified coronary 
plaque compared with HIV-uninfected individuals inde-
pendently by cardiovascular risk.
On these basis, recently, an increasing number of HIV 
patients undergo invasive cardiovascular procedures 
as a result of acute cardiovascular events or severe ath-
erosclerotic disease. Although percutaneous coronary 
intervention (PCI) frequently used to treat coronary 
artery disease in HIV, little is known regarding the out-
comes and the effects of immune activation on the this 
procedure.
In literature an observational study on 50 HIV infected 
patients undergoing PCI found that this procedure is a 
safe treatment strategy of coronary revascularization in 
HIV positive patients without significant differences in 
terms of clinical restenosis from the control population 
[43].
On the other hand Martín-Reyes et  al. [44] reported 
that in-hospital prognosis in patients with HIV, under-
going PCI, was worse than in control subjects: in fact 
HIV-positive patients presented a lower rate of PCI suc-
cess (75 vs. 85 %) respect HIV-negative patients. Moreo-
ver Segev et al. [45] analyzing the long-term outcome of 
PCI in 12 HIV-infected patients, observed that 58.3  % 
of subjects suffered from severe clinical and/or angio-
graphic restenosis requiring additional interventions 
or causing severe angina pectoris. They concluded that 
HIV-infected patients should be considered as high risk 
group and treated routinely with drug-eluting stents but 
they did not given any pathogenic interpretation of their 
observations. Although HIV-infected patients have a 
higher incidence of post-PCI ischemic events, resteno-
sis, and stent thrombosis, Matetzky underlined that the 
intermediate-term mortality is low [46].
At this moment few data are available regarding the 
pathogenesis of restenosis after coronary revasculariza-
tion in HIV positive patients. It is possible that the con-
comitant presence of traditional risk factors, assumption 
of antiretroviral therapy and his metabolic complications 
contribute to the restenosis events after PCI in HIV-pos-
itive population. However, although the presence of these 
well-known reasons of atherogenesis, the rapidity of pro-
gression of atherosclerosis and restenosis process seems 
linked principally to chronic inflammation and excess 
immune activation in HIV-infected patients [47–49]. In 
fact chronic HIV infection is characterized by multifac-
eted systemic immune activation, including increased 
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frequencies of activated T-cells and increased turnover 
of T-cells that correlate directly with disease progression 
[50]. Moreover a previous study have described other 
conditions (coronary allograft vasculopathy, native ath-
erosclerosis) associated with an inappropriate inflam-
matory reactivity that may predispose to re-stenosis 
after PCI [51]. For these reasons therapies that reduce 
immune activation may be of benefit, particularly for 
such individuals [50, 52]; moreover a strictly monitoring 
of coronary atherosclerosis is required in management of 
HIV-infected patients with concomitant non-traditional 
risk factors for intense immune-activation.
In summary contrasting results are reported in the 
literature on the outcome of coronary revasculariza-
tion; moreover the coronary revascularization with PCI 
and stents seems to be influenced by the excess of HIV 
related inflammation and immune activation [53]. Large 
clinical studies are needed to clarify aspects of the matter 
is not yet resolved.
New therapeutic insights in minimizing the risk 
of cardiovascular disease
As previously highlighted, HIV-infected patients experi-
enced a premature and accelerated aging probably driven 
by chronic inflammation and persistent immune activa-
tion. For this reason currently immunological therapeutic 
strategies and virological interventions are investigated 
with the aim of controlling the levels of immune activa-
tion and then reducing the impact of CVD promoted by 
chronic inflammation.
An innovative immunological/pharmacological inter-
vention, granted by experience in HIV negative popu-
lations, is based on use of statins. These class of drugs, 
widely used for primary prevention of atherosclerotic 
CVD, are known to decrease cholesterol level as well as 
inflammation in HIV seronegative patients. For example 
in the JUPITER trial rosuvastatin significantly reduced 
all-cause mortality and in particular the incidence of 
major cardiovascular events in healthy persons without 
hyperlipidemia but with elevated hsCRP levels, a well-
known marker of inflammation [54]. Statins will emerge 
also as potential components of the therapeutic arma-
mentarium for chronic inflammatory and autoimmune 
pathologies which share some pathogenetic aspects con-
cerning chronic inflammation with HIV infection [55]. 
In fact statin therapy has been shown to reduce disease 
severity in patients with rheumatoid arthritis (RA) and to 
improve endothelium-dependent vasodilation in patients 
with RA and systemic lupus erythematosus (SLE) [56–
60]. In systemic inflammatory diseases (such as RA, SLE, 
inflammatory bowel diseases, psoriasis, spondyloarthritis 
and others) multiple factors, including tumor necrosis 
factor-α (TNF-α), circulating inflammatory cytokines, 
reactive oxygen species, autoantibodies, and oxidized 
low density lipoprotein (LDL) directly and indirectly 
activate endothelial cells, increased endothelial perme-
ability, increased leukocyte adhesion and generation of 
a pro-thrombotic state. In this case statins could have 
a potential role in modifying initiation and amplifica-
tion of immune inflammatory responses and their anti-
inflammatory activity is linked to different mechanisms 
including (but not limited) the decrease in chemotaxis 
of monocytes and macrophages, the lipopolysaccharide 
(LPS) mediated release of TNF-α, and the activation of 
NO synthase [61–64].
The efficacy and safety of different statins for HIV-
infected individuals in the primary prevention setting 
remain to be established. Also the effect of statins use on 
overall mortality in HIVpositive patients remains contro-
versial [65, 66].
A recent meta-analysis, including 18 clinical studies 
with 736 HIV-positive patients under cART treated with 
statins in the primary prevention, showed that this ther-
apy significantly lowers plasma total cholesterol (TC) and 
low density lipoprotein (LDL) levels. In particular rosuv-
astatin 10 mg and atorvastatin 10 mg provided the larg-
est reduction in TC levels while atorvastatin 80 mg and 
simvastatin 20 mg had the largest reduction in LDL [67].
Moreover atorvastatin and rosuvastatin appear to 
reduce non-calcified coronary plaque volume and slow 
progression of carotid intima-media thickness in HIV 
positive patients under cART [68].
Conversely the effects of statins on inflammation and are 
less conclusive at the moment: a recent study, evaluating 
the effect of rosuvastatin on markers of immune activation 
in treatment-naive HIV-patients, showed that this mol-
ecule had a small but significant positive effect on CD4/
CD8 T cell ratio, but not influenced other activation mark-
ers (neopterin, soluble Toll-like receptor (TLR) 2, sTLR4, 
interleukin (IL)-6, IL-1Ra, IL-18, D-dimer, hsCRP) [69]. 
Interesting the protective effect of statins on CV system is 
related not only to their anti-inflammatory activity but also 
to a control of oxidative stress: in fact oxidative stress plays 
a significant role in atherosclerosis development and is also 
elevated in HIV+ patients due to excessive production of 
free radicals that play a major role in oxidative modifica-
tion in LDL particle. Serum oxidized LDL levels may con-
tribute to monocyte activation, are associated with clinical 
manifestations of atherosclerosis, decreases in response to 
statin therapy and relates independently to reductions in 
coronary plaque in patients with HIV. Statins may reduce 
oxidative stress and subsequently subclinical vascular dis-
ease in HIV but further study in the context of HIV disease 
is warranted [70–72].
Considered the importance of the topic and the still 
existing doubts, the US National Institutes of Health 
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(NIH) recently launched the REPRIEVE trial to defini-
tively assess the efficacy of statins as a primary preven-
tion strategy for CVD in this at-risk population. This 
clinical study launched in 2015 is the largest ongoing trial 
of HIV-related CVD to date (see Table 2) [73].
Some concerns are the potential side effects described 
for these class of drugs. i.e. statin use was found associ-
ated with a modestly increased risk of incident diabetes 
mellitus in HIV  Outpatient Study (HOPS) participants 
[74]. Also severe  rhabdomyolysis, hepatotoxicity  and 
acute renal failure were described in HIV positive popu-
lation [75–77]. Concerns are also the potential numerous 
drug–drug interactions with cART dependent on statins’ 
pharmacokinetic profile: i.e. simvastatin and lovasta-
tin, metabolized through cytochrome P450 (CYP) 3A, 
have the significant potency for drug–drug interaction 
with potent CYP3A inhibitors such as ritonavir- or cobi-
cistat-boosted HIV-protease inhibitors (PIs). Less potent 
drug–drug interactions have been reported for atorvas-
tatin although it is also a CYP3A substrate. Non-CYP3A-
dependent  statin  concentrations are also affected when 
co-administered with PIs, mainly through interaction 
with OATP1B1 [78, 79].
Interesting pitavastatin, a newer statin that does not 
have substantial interactions with antiretroviral drugs, 
will be tested in the REPRIEVE trial. At the present time, 
however, many aspects of potential drug interactions 
remain to be clarified. Despite all the warnings described, 
the overall use of statins in HIV population is associated 
with low rates of adverse events and the mean discontin-
uation rate reported in meta-analysis and attributable to 
these problems was 0.12 per 100 person-years [95 % CI 
(0.05, 0.20)] [67].
The possibility that residual immune activation (and 
the consequent inflammation) is related to persistent 
virus replication has suggested that more potent anti-
retroviral regimen (i.e., ART “intensification”) may be 
more effective in reducing the HIV-associated immune 
activation. In one study intensification was carried out 
for 10  weeks with cART regimens (atazanavir/ritonavir, 
lopinavir/ritonavir, efavirenz) consisting of drugs that 
were not used previously in the enrolled patients. Since 
the median levels of viremia were not significantly dif-
ferent between pre-intensification and post-intensifi-
cation period, the authors concluded that the levels of 
residual virus replication, and thus immune activation, 
may depend on the size of stable reservoir compartments 
that are established prior to the initiation of cART [80]. 
Another study of Llibreet et  al. [81] assigned randomly 
69 patients with undetectable levels of viraemia for more 
than 1  year to treatment groups in which 45 intensify 
therapy with raltegravir and 24 continue the same ther-
apy for 48 weeks. The author observed after 24 weeks in 
the group of intensification therapy a reduction of the 
size of the reservoirs and of the levels of immune activa-
tion (measured as fraction of CD8+  T-cells expressing 
CD38+ and/or HLA-DR). Further studies on the effects 
of cART intensification on the residual immune acti-
vation will be needed to ascertain whether a complete 
recovery of the “ideal” pre-HIV infection immune sys-
tem function can be achieved through virological inter-
ventions alone. In absence of conclusive results in this 
research field, the alternative possibilities, i.e. specific 
immune-based interventions, will be necessary to try to 
protect HIV infected individuals by damages of immune 
activation. In this sense we know that the most important 
source of the status of generalized inflammation is attrib-
uted to the breakdown in the integrity of the gut mucosa 
with the increase of microbial translocation and the 
transition of the microbial products in the systemic cir-
culation. For this reason different trials were conducted 
to explore the possibility of intervention on this source 
of chronic inflammation. In a recent study in order to 
enhance GI tract immunity, we recruited and treated 20 
HIV-infected humans with cART supplemented with 
probiotics and followed inflammation and immuno-
logical parameters. We observe that cART did not nor-
malize the levels of immune activation in HIV positive 
patients, anyway inflammation and markers of microbial 
translocation were significantly reduced with probiotic 
supplementation. Patients enrolled showed a clear and 
statistically significant reduction in the levels of immune 
activation on CD4 T-lymphocytes, for both markers 
CD38 and HLA-DR and their simultaneous expression, 
LBP and hsCRP plasma levels after probiotic diet sup-
plementation. In conclusion this study, like other recent 
reports [82–85], evidenced that supplementing cART 
with probiotics in HIV-infected individuals may improve 
GI tract immunity and thereby mitigate inflammatory 
sequelae, ultimately improving prognosis [86].
Another potentially interesting therapeutic concept for 
the reduction of high levels of inflammation and to con-
trol CVD is to use non pharmacological tools of interven-
tion such as physical activity. Several published studies 
indicate that physical activity could represent a benefi-
cial non-pharmacological intervention to reduce chronic 
inflammation. Currently available data are limited, none-
theless increasing evidence suggests that the introduction 
of regular physical exercise in the clinical management 
of HIV-infected individuals may have a significant thera-
peutic impact in reducing inflammation and CVD. For 
example Longo et al. [87] conducted a longitudinal study 
on 50 ART-treated HIV-infected patients with sedentary 
life style to evaluate the effect of 12  weeks of moderate 
intensity exercise on parameters of immune activation 
and metabolic profile. At the enrollment and at 12 weeks 
Page 14 of 17d’Ettorre et al. AIDS Res Ther  (2016) 13:21 
all participants were assessed by a 6-min walking test and 
1-RM, DEXA, metabolic and immune-virologic param-
eters, and markers of immune activation (IL-6, d-Dimer, 
sCD14 and IL-18). The authors found a significant 
improvement of both fitness and immune activation at 
the week-12 time point.
On the basis of these evidences, several authors pro-
posed that regular physical exercise should be further 
studied as a potential anti-inflammatory, non-pharmaco-
logical approach to be used to treat HIV residual disease 
and non-AIDS-defining illnesses in cART-treated HIV-
infected individuals [88–94].
Likewise, lifestyle interventions are another non phar-
macological tool reputed able to reduce cardiovascular risk 
in general population: nevertheless a recent randomized 
pilot study with a follow-up 36  months evidenced that a 
multidisciplinary lifestyle intervention resulted in a slight 
improvement in some cardiovascular risk factors and did 
not prevent cIMT progression in HIV-infected patients 
with Framingham scores  >10  % [95]. Further studies are 
required to confirm the importance of all these data.
Conclusions
In cART treated HIV-infected individuals with undetect-
able viremia the level of immune activation is dramati-
cally reduced compared to baseline (i.e., pre-treatment) 
but rarely goes back to normal levels. This immune 
activation is associated with long-term sequelae of HIV 
infection such as accelerated atherosclerosis, neurologi-
cal disease, and several other conditions that may modify 
the quality of life of HIV-infected subjects. In addition, 
the residual viral replication appears to be a uncontrolled 
determinant of the levels of immune activation in HIV 
patients treated with cART.
The goal of practitioners is changed in the last years: 
in fact if initially it was to reach undetectable plasma 
levels of HIV viremia, now it is to prevent the prema-
ture aging and improve the quality of life of all patients. 
For this reason it becomes necessary to control the hid-
den effects of HIV, to develop safe antiretroviral regimen 
and discover new scores to predict the non AIDS related 
manifestations.
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